ArticleJournal of thoracic disease2025
A bibliometric analysis of research trends and global perspectives on lung large cell neuroendocrine cancer.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung large cell neuroendocrine carcinoma (LCNEC) is a malignant neoplasm derived from neuroendocrine cell precursors, accounting for only 1-3% of all lung cancer cases. This carcinoma is characterized by considerable invasiveness and heterogeneity, with a poor prognosis evidenced by a 5-year survival rate of less than 15%. This article aims to enhance thoracic surgeons' understanding of the current status, latest developments, and emerging trends in this field, in order to provide reference for future related research. Methods: We performed a systematic review of 694 articles sourced from the Web of Science Core Collection (WoSCC) database to evaluate global research trends in LCNEC from January 2000 to December 2024. Bibliometric analysis was conducted utilizing software tools including R Studio and CiteSpace 5.8 R5. This comprehensive, multi-dimensional analysis focused on key aspects such as researchers, institutions, countries, and the body of published literature. Results: The United States and Japan have assumed prominent leadership positions in research, whereas contributions from China and Europe are progressively expanding. Traditional pathological descriptions have evolved to become more comprehensive, with molecular subtyping and precision therapy emerging as focal points of current research. Conclusions: Future endeavors should prioritize strengthening global collaboration in this field and advancing prospective clinical trials. Furthermore, the advancement of multi-omics analysis and precision medicine holds significant potential to enhance the future treatment paradigm for LCNEC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.